Julie Gralow, MD | Authors


Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast Cancer

August 12, 2020

Julie Gralow, MD, discusses the primary analysis of trastuzumab emtansine plus pertuzumab versus trastuzumab, pertuzumab, and taxane, after anthracyclines as adjuvant therapy in patients with high-risk HER2-positive early breast cancer in the of the KAITLIN study.

Investigating How to Help Patients With Breast Cancer Stay on Therapy

June 25, 2020

Julie Gralow, MD, discusses the use of patient-reported outcomes in the SWOG S1105 trial and different factors for patients with early-stage breast cancer on an aromatase inhibitor to see if they could predict who may be more likely to stop taking treatment early.

Dr. Julie Gralow on the Importance of Genetic Testing for Breast Cancer

October 26, 2015

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, talks about the importance of women knowing which genetic tests they�ve previously had done for breast cancer.